Related references
Note: Only part of the references are listed.Identification of a novel KLC1-ROS1 fusion in a case of pediatric low-grade localized glioma
Yoshiko Nakano et al.
BRAIN TUMOR PATHOLOGY (2019)
cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation
David W. Ellison et al.
ACTA NEUROPATHOLOGICA (2019)
Brainstem pilocytic astrocytoma with H3 K27M mutation: case report
Shuhei Morita et al.
JOURNAL OF NEUROSURGERY (2018)
Diffuse high-grade gliomas with H3 K27M mutations carry a dismal prognosis independent of tumor location
Michael Karremann et al.
NEURO-ONCOLOGY (2018)
Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas
Drew Pratt et al.
ACTA NEUROPATHOLOGICA (2018)
cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2018)
cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC)
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2018)
Molecular, Pathological, Radiological, and Immune Profiling of Non-brainstem Pediatric High-Grade Glioma from the HERBY Phase II Randomized Trial
Alan Mackay et al.
CANCER CELL (2018)
H3 K27M-mutant gliomas in adults vs. children share similar histological features and adverse prognosis
Bette K. Kleinschmidt-DeMasters et al.
CLINICAL NEUROPATHOLOGY (2018)
BRAF V600E Status Alone Is Not Sufficient as a Prognostic Biomarker in Pediatric Low-Grade Glioma
David T. W. Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
DNA methylation-based classification of central nervous system tumours
David Capper et al.
NATURE (2018)
Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors
Kohei Fukuoka et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2018)
Co-occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma
Melanie Pages et al.
BRAIN PATHOLOGY (2018)
BRAF V600E mutation is a significant prognosticator of the tumour regrowth rate in brainstem gangliogliomas
Xin Chen et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2017)
Genomic Analysis of Childhood Brain Tumors: Methods for Genome-Wide Discovery and Precision Medicine Become Mainstream
Stephen C. Mack et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Medulloblastoma: From Myth to Molecular
Vijay Ramaswamy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas
Alvaro Lassaletta et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Diffuse Midline Gliomas with Histone H3-K27M Mutation: A Series of 47 Cases Assessing the Spectrum of Morphologic Variation and Associated Genetic Alterations
David A. Solomon et al.
BRAIN PATHOLOGY (2016)
New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs
Dominik Sturm et al.
CELL (2016)
Pediatric thalamic glioma with H3F3A K27M mutation, which was detected before and after malignant transformation: a case report
Kenichi Ishibashi et al.
CHILDS NERVOUS SYSTEM (2016)
BRAF Mutation Correlates With High-Risk Langerhans Cell Histiocytosis and Increased Resistance to First-Line Therapy
Sebastien Heritier et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma
Scott Ryall et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2016)
A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation
Cheng-Ying Ho et al.
ACTA NEUROPATHOLOGICA (2015)
BRAF mutation and anaplasia may be predictive factors of progression-free survival in adult pleomorphic xanthoastrocytoma
E. Tabouret et al.
EJSO (2015)
BRAF Mutation and CDKN2A Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma
Matthew Mistry et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Evidence for BRAF V600E and H3F3A K27M double mutations in paediatric glial and glioneuronal tumours
A. T. Nguyen et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2015)
Current understanding of BRAF alterations in diagnosis, prognosis, and therapeutic targeting in pediatric low-grade gliomas
Catherine Louise Penman et al.
FRONTIERS IN ONCOLOGY (2015)
Development of a robust and sensitive pyrosequencing assay for the detection of IDH1/2 mutations in gliomas
Hideyuki Arita et al.
BRAIN TUMOR PATHOLOGY (2015)
The landscape and therapeutic relevance of cancer-associated transcript fusions
K. Yoshihara et al.
ONCOGENE (2015)
BRAF V600E and TERT Promoter Mutations Cooperatively Identify the Most Aggressive Papillary Thyroid Cancer With Highest Recurrence
Mingzhao Xing et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Epigenomic alterations define lethal CIMP-positive ependymomas of infancy
S. C. Mack et al.
NATURE (2014)
The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma
Gang Wu et al.
NATURE GENETICS (2014)
Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas
Jinghui Zhang et al.
NATURE GENETICS (2013)
K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas
Dong-Anh Khuong-Quang et al.
ACTA NEUROPATHOLOGICA (2012)
The Association of the BRAFV600E Mutation With Prognostic Factors and Poor Clinical Outcome in Papillary Thyroid Cancer
Tae Hyuk Kim et al.
CANCER (2012)
Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma
Hendrik Witt et al.
CANCER CELL (2011)
Tandem Duplication Producing a Novel Oncogenic BRAF Fusion Gene Defines the Majority of Pilocytic Astrocytomas
David T. W. Jones et al.
CANCER RESEARCH (2008)
Share Paper
